Protopic, Elidel Need “Black Box” Warning On Cancer Risk, FDA Cmte. Says
Executive Summary
FDA's Pediatric Advisory Committee is recommending a "black box" warning for Novartis' Elidel and Fujisawa's Protopic based on a carcinogenicity risk with the eczema treatments
You may also be interested in...
Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling
Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)
Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling
Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)
Elidel, Protopic “Black Box” Could Be Test Of FDA’s Labeling Authority
FDA's proposal to add a "black box" to labeling of the eczema treatments Elidel and Protopic could be a high-profile test of the agency's ability to change product labeling following recent congressional discussion of the agency's authority